한글목차

주의력 결핍 과잉행동장애(ADHD) 치료제 세계 시장은 2030년까지 577억 달러에 달할 전망

2023년에 346억 달러로 추정되는 주의력 결핍 과잉행동장애(ADHD) 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 7.6%로 성장하고, 2030년에는 577억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 각성제는 CAGR 7.1%로 성장을 지속하고, 분석 기간 종료 시 477억 달러에 달할 것으로 예측됩니다. 비자극제 부문의 성장률은 분석 기간 동안 CAGR 10.1%로 추정됩니다.

미국 시장은 92억 달러, 중국은 CAGR 7.1%로 성장할 것으로 예측

미국의 주의력 결핍 과잉행동장애(ADHD) 치료제 시장은 2023년 92억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 90억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 7.1%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 6.7%와 6.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 5.9%로 성장할 것으로 예측됩니다.

주의력 결핍 과잉행동장애(ADHD) 치료제 - 주요 동향 및 촉진요인

주의력 결핍 과잉행동장애(ADHD)는 기능과 발달을 방해하는 부주의, 다동성, 충동성의 지속적인 패턴을 특징으로하는 신경 발달 장애입니다. ADHD는 일반적으로 어린 시절에 발병하여 성인기까지 계속될 수 있으며 학업 성적, 직업, 사회적 교류 등 삶의 다양한 측면에 영향을 미칩니다. 이 질환은 일반적으로 행동 증상에 따라 진단되며, 치료에는 행동 요법, 교육적 개입, 약리학적 치료가 조합되는 경우가 많습니다. 약물 요법은 ADHD 관리의 핵심이며 증상의 상당한 완화를 초래합니다. 이러한 치료는 자극제와 비 자극제로 크게 나뉩니다. 메틸페니데이트와 암페타민과 같은 자극제는 가장 잘 처방되며 주의력을 높이고 다동성과 충동적인 행동을 줄이는 효과가 있는 것으로 알려져 있습니다. 아토목세틴 및 특정 항우울제와 같은 비자극제는 자극제에 반응하지 않는 환자나 부작용을 겪는 환자에게 대체 약물을 제공합니다.

ADHD 치료제 시장은 이 질병에 대한 이해의 심화와 약리학의 진보로 지난 수십년동안 크게 발전해 왔습니다. 서방형 제형의 개발은 ADHD 치료에 혁명을 일으켰고, 하루에 한 번 복용하면 복용 어드히어런스를 개선하고 하루 종일 일관된 증상 조절을 가능하게 했습니다. 또한, 새로운 비자극제의 도입은 치료 옵션을 넓히고 다양한 요구와 선호도를 가진 환자를 수용합니다. 제약 회사는 ADHD에 관여하는 다양한 경로를 표적으로 하는 새로운 치료제를 개발하는 연구에 적극적으로 노력하고 있습니다. 여기에는 현재의 약물로 전통적으로 표적으로 되어 있는 도파민과 노르에피네프린 이외의 신경전달물질의 역할을 탐구하는 것도 포함됩니다. 또한, 효과를 최적화하고 부작용을 최소화하기 위해 유전적, 환경적, 라이프스타일 요인에 따라 치료를 조정하는 것을 목표로 하는 개인화된 의료 접근법에 대한 관심이 높아지고 있습니다.

ADHD 치료제 시장의 성장은 여러 요인에 의해 야기됩니다. 진단기술의 진보와 ADHD에 대한 인지도의 향상은 진단률의 상승으로 이어져 환자층의 확대로 이어지고 있습니다. 특히 성인에서 ADHD의 유병률 상승도 시장 성장에 기여합니다. 서방형 제형 및 경피 패치와 같은 약물 전달 시스템의 기술적 진보는 환자의 충동과 만족도를 증가시킵니다. 게다가 디지털 치료제와 원격 의료 플랫폼의 개발은 특히 원격지나 의료 서비스가 없는 지역에서 ADHD 치료에 대한 접근성을 향상시킵니다. 정신 건강 문제의 수용이 진행됨에 따라 ADHD와 관련된 편견이 감소함에 따라 더 많은 사람들이 치료를 받고 있습니다. 또한, 새로운 약리학적 표적의 발견과 기존 치료법의 개선을 목표로 하는 연구개발의 지속적인 노력이 시장을 전진시킬 것으로 기대되고 있습니다. 제약 회사는 또한 마케팅 및 교육 캠페인에 투자하여 치료의 이점에 대한 인식을 높이고 조기 진단과 조기 개입을 촉진합니다. 이러한 요인은 종합적으로 ADHD 치료제 시장의 견조한 성장과 지속적인 진화를 보장합니다.

조사 대상 기업 예(주목의 27사)

• Alcobra Ltd.
• Amarantus Bioscience Holdings, Inc.
• Curemark, LLC
• Eli Lilly and Company
• Intellipharmaceutics International, Inc.
• Janssen Global Services, LLC
• Mallinckrodt PLC
• Mylan NV
• Neos Therapeutics, Inc.
• Neurovance, Inc.
• Noven Pharmaceuticals, Inc.
• Pfizer Inc.
• Shire plc
• Supernus Pharmaceuticals, Inc.
• Tris Pharma, Inc.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach US$57.7 Billion by 2030

The global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$34.6 Billion in the year 2023, is expected to reach US$57.7 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Stimulant Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$47.7 Billion by the end of the analysis period. Growth in the Non-Stimulant Drugs segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.2 Billion While China is Forecast to Grow at 7.1% CAGR

The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$9.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.0 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Key Trends and Drivers

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. ADHD typically presents in childhood and can continue into adulthood, affecting various aspects of life including academic performance, work, and social interactions. The disorder is commonly diagnosed based on behavioral symptoms, and treatment often involves a combination of behavioral therapies, educational interventions, and pharmacological treatments. Pharmacological therapies are a cornerstone of ADHD management, providing significant symptomatic relief. These treatments are broadly classified into stimulant and non-stimulant medications. Stimulants such as methylphenidate and amphetamines are the most commonly prescribed and are known for their efficacy in increasing attention and reducing hyperactive and impulsive behaviors. Non-stimulant medications, including atomoxetine and certain antidepressants, offer alternatives for patients who do not respond well to stimulants or who experience adverse effects.

The ADHD therapeutics market has evolved significantly over the past few decades, driven by a growing understanding of the disorder and advancements in pharmacology. The development of extended-release formulations has revolutionized ADHD treatment, offering once-daily dosing that improves adherence and provides consistent symptom control throughout the day. Additionally, the introduction of new non-stimulant medications has expanded treatment options, catering to patients with diverse needs and preferences. Pharmaceutical companies are actively engaged in research to develop novel therapeutics that target different pathways involved in ADHD. This includes exploring the role of neurotransmitters other than dopamine and norepinephrine, which are traditionally targeted by current medications. Furthermore, there is increasing interest in personalized medicine approaches, which aim to tailor treatments based on genetic, environmental, and lifestyle factors to optimize efficacy and minimize side effects.

The growth in the ADHD therapeutics market is driven by several factors. Advances in diagnostic techniques and increasing awareness about ADHD are leading to higher diagnosis rates, thereby expanding the patient pool. The rising prevalence of ADHD, particularly in adults, is also contributing to market growth. Technological advancements in drug delivery systems, such as extended-release formulations and transdermal patches, are enhancing patient adherence and satisfaction. Additionally, the development of digital therapeutics and telemedicine platforms is improving access to ADHD care, especially in remote and underserved areas. The increasing acceptance of mental health issues and reduction in stigma associated with ADHD are encouraging more individuals to seek treatment. Furthermore, ongoing research and development efforts aimed at discovering new pharmacological targets and improving existing therapies are expected to drive the market forward. Pharmaceutical companies are also investing in marketing and educational campaigns to raise awareness about the benefits of treatment and encourage early diagnosis and intervention. These factors collectively ensure the robust growth and continued evolution of the ADHD therapeutics market.

Select Competitors (Total 27 Featured) -

• Alcobra Ltd.
• Amarantus Bioscience Holdings, Inc.
• Curemark, LLC
• Eli Lilly and Company
• Intellipharmaceutics International, Inc.
• Janssen Global Services, LLC
• Mallinckrodt PLC
• Mylan NV
• Neos Therapeutics, Inc.
• Neurovance, Inc.
• Noven Pharmaceuticals, Inc.
• Pfizer Inc.
• Shire plc
• Supernus Pharmaceuticals, Inc.
• Tris Pharma, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advances in Diagnostic Techniques Propel Growth in ADHD Therapeutics Market
  • Increasing Awareness about ADHD Expands Addressable Market Opportunity
  • Rising Prevalence of ADHD in Adults Spurs Demand for Therapeutic Solutions
  • Development of Extended-Release Formulations Enhances Patient Adherence and Satisfaction
  • Technological Innovations in Drug Delivery Systems Strengthen Business Case for ADHD Medications
  • Introduction of Non-Stimulant Medications Generates New Market Opportunities
  • Growing Acceptance of Mental Health Issues Accelerates Demand for ADHD Therapies
  • Expansion of Digital Therapeutics and Telemedicine Platforms Improves Access to ADHD Care
  • Increasing Focus on Comorbid Conditions Expands Therapeutic Options for ADHD Patients
  • Advances in Neuroimaging and Biomarker Research Generate Insights for Innovative Treatments
  • Development of Combination Therapies Enhances Efficacy and Patient Outcomes
  • Expanding Pediatric Population Drives Demand for ADHD Treatments
  • Integration of Behavioral and Pharmacological Therapies Generates Comprehensive Care Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Non-Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• JAPAN
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• CHINA
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• EUROPE
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• FRANCE
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 71: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 74: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• GERMANY
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 80: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 89: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 98: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 101: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 125: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
  • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION